stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Return on assets
argenex SE's return on assets over the twelve months to 30 September 2026 was 0.00%, down 17.4 percentage points from fiscal 2025 (17.4%). Over the past ten years it has ranged from −31.3% (fiscal 2020) to 17.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 17.4% | 1.85 |
| FY2024 | 15.5% | 23.20 |
| FY2023 | −7.69% | 16.02 |
| FY2022 | −23.7% | (7.79) |
| FY2021 | −15.9% | 15.41 |
| FY2020 | −31.3% | (15.38) |
| FY2019 | −16.0% | (1.67) |
| FY2018 | −14.3% | (2.45) |
| FY2017 | −11.8% | (3.44) |
| FY2016 | −8.39% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 11.4% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| ARGX argenex SE | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| MRNA Moderna, Inc. compare | −27.4% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement